Repositioning Candidate Details
| Candidate ID: | R0981 |
| Source ID: | DB06324 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | XmAb 2513 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for the treatment of hodgkin’s lymphoma. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | XmAb™2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. XmAb™2513 has an XmAb™ Fc domain which increases its cytotoxic potency. XmAb™2513 recruits primary human immune cells to kill tumor cells in vitro models and is active in blocking tumor growth in rodent models. |
| Targets: | Tumor necrosis factor receptor superfamily member 8 |
| Inclusion Criteria: | Target associated |
